Compare CNTY & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNTY | OTLK |
|---|---|---|
| Founded | 1992 | 2010 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.1M | 38.7M |
| IPO Year | N/A | N/A |
| Metric | CNTY | OTLK |
|---|---|---|
| Price | $1.50 | $0.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $3.67 | ★ $3.83 |
| AVG Volume (30 Days) | 38.8K | ★ 1.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.20 | $1,425.11 |
| Revenue Next Year | $7.18 | $129.89 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.23 | $0.38 |
| 52 Week High | $3.26 | $3.39 |
| Indicator | CNTY | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 44.23 | 33.77 |
| Support Level | $1.48 | $0.38 |
| Resistance Level | $1.53 | $0.53 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 14.41 | 28.11 |
Century Casinos Inc is a casino entertainment company that develops and operates gaming establishments as well as related lodging, restaurants, horse racing (including off-track betting), and entertainment facilities in North America. The company has three reportable segments based on the geographical locations in which its casinos operate; United States; Century Casino & Hotel-Central City, and Century Casino & Hotel-Cripple Creek in Colorado, Mountaineer Casino, Racetrack & Resort in West Virginia, and Century Casino Caruthersville, and Century Casino Cape Girardeau in Missouri, Canada; Century Casino & Hotel, Century Casino St. Albert, Century Mile Racetrack in Edmonton and Casino Century Downs Racetrack and Casino in Calgary, and Poland; Casinos Poland.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.